Search Within

Dana Elizabeth Rathkopf

Formats
  1. Meeting Abstract (160)
  2. Journal Article (106)
  3. Review (4)
  4. Editorial (3)
  5. Correspondence (1)
Groups
  1. Department of Medicine (274)
  2. Genitourinary Oncology Service (274)
  3. Solid Tumor Oncology Division (274)
  4. Hematologic Malignancies, Division of (70)
  5. GSK Faculty (53)
  6. Human Oncology and Pathogenesis Program (41)

More Groups

People
  1. Howard Scher (133)
  2. Michael Morris (79)
  3. Susan Slovin (59)
  4. Daniel Danila (45)
  5. Karen Autio (34)
  6. Wassim Abida (31)

More People

Years
  1. 2025 (10)
  2. 2024 (20)
  3. 2023 (19)
  4. 2022 (16)
  5. 2021 (18)
  6. 2020 (12)

More Years

Publications
  1. Journal of Clinical Oncology (121)
  2. Annals of Oncology (27)
  3. European Urology (16)
  4. Clinical Cancer Research (13)
  5. Cancer Research (9)
  6. European Journal of Cancer (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (124)
  2. Oxford University Press (28)
  3. American Association for Cancer Research (26)
  4. Elsevier Science, Inc. (24)
  5. Elsevier Inc. (16)
  6. Nature Publishing Group (9)

More Publishers

Results (274)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE
    Meeting Abstract

    Chi, K. N. N.; Castro, E.; Attard, G.; Smith, M. R.; Sandhu, S. K.; Efstathiou, E.; Roubaud, G.; Small, E. J. J.; Gomes, A. J. P. D. S; Rathkopf, D.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial
    Meeting Abstract

    Attard, G.; Sandhu, S. K.; Rathkopf, D.; Castro, E.; Saad, M.; Smith, M. R.; Small, E. J. J.; Olmos, D.; Gomes, A. J. P. D. S; Roubaud, G.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade
    Journal Article

    Harrold, E. C.; Foote, M. B.; Rousseau, B.; Walch, H.; Kemel, Y.; Richards, A. L.; Keane, F.; Cercek, A.; Yaeger, R.; Rathkopf, D.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US
    Journal Article

    Rencsok, E. M.; Slopen, N.; Autio, K.; Morgans, A.; McSwain, L.; Barata, P.; Cheng, H. H.; Dreicer, R.; Heath, E.; McKay, R. R.; more...
    Quality of Life Research (2023)

    Fulltext@MSK | Save
  • FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)
    Meeting Abstract

    Nguyen, P. L.; Kollmeier, M. A.; Rathkopf, D.; Hoffman, K. E.; Zurita-Saavedra, A.; Spratt, D. E.; Dess, R. T.; Liauw, S.; Szmulewitz, R.; Einstein, D. J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial
    Meeting Abstract

    McKay, R. R.; Xie, W.; Yang, X.; Rathkopf, D. E.; Laudone, V. P.; Bubley, G.; Einstein, D. J.; Chang, P.; Wagner, A.; Kane, C. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
    Journal Article

    Chi, K. N.; Rathkopf, D.; Smith, M. R.; Efstathiou, E.; Attard, G.; Olmos, D.; Lee, J. Y.; Small, E. J.; Gomes, Ajpds; Roubaud, G.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: Second interim analysis of the randomized phase III MAGNITUDE trial
    Journal Article

    Chi, K. N.; Sandhu, S.; Smith, M. R.; Attard, G.; Saad, M.; Olmos, D.; Castro, E.; Roubaud, G.; Pereira de Santana Gomes, A. J.; Small, E. J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • External validation of a prognostic model of overall survival in men with chemotherapy-naìˆve metastatic castration-resistant prostate cancer
    Journal Article

    Halabi, S.; Yang, Q.; Roy, A.; Luo, B.; Araujo, J. C.; Logothetis, C.; Sternberg, C. N.; Armstrong, A. J.; Carducci, M. A.; Chi, K. N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 3 MAGNITUDE study: Results from second interim analysis of niraparib with abiraterone acetate and prednisone as first-line therapy in patients with metastatic castration-resistant prostate cancer with and without HRR gene alteration
    Meeting Abstract

    Rathkopf, D. E.; Small, E.; Guckert, M.; Chi, K. N.
    Oncology Nursing Forum (2023)

    Fulltext@MSK | Save